An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes

Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regul...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alessandra Puddu, François Mach, Alessio Nencioni, Giorgio Luciano Viviani, Fabrizio Montecucco
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Series:	Mediators of Inflammation
Online Access:	http://dx.doi.org/10.1155/2013/591056
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
by: Alessandra Puddu, et al.
Published: (2013-01-01)

Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis
by: Roberta Sanguineti, et al.
Published: (2014-01-01)

Effects of High Glucose Levels and Glycated Serum on GIP Responsiveness in the Pancreatic Beta Cell Line HIT-T15
by: Alessandra Puddu, et al.
Published: (2015-01-01)

Evidence for the Gut Microbiota Short-Chain Fatty Acids as Key Pathophysiological Molecules Improving Diabetes
by: Alessandra Puddu, et al.
Published: (2014-01-01)

Advanced Glycation End-Products and Hyperglycemia Increase Angiopoietin-2 Production by Impairing Angiopoietin-1-Tie-2 System
by: Alessandra Puddu, et al.
Published: (2019-01-01)

Role of Mitogen-Activated Protein Kinase Pathways in Multifactorial Adverse Cardiac Remodeling Associated with Metabolic Syndrome
by: Mohamed Asrih, et al.
Published: (2013-01-01)

Glucagon-Like Peptide-2: New Insights-New Questions
by: Gordon R Greenberg
Published: (2001-01-01)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
by: XingChun Wang, et al.
Published: (2015-01-01)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
by: Nada K. Al-Ghurayr, et al.
Published: (2023-01-01)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
by: Marie Kjaer, et al.
Published: (2020-01-01)

Perioperative glucagon-like peptide-1 receptor agonists–induced gastroparesis – Is gastric ultrasound the answer?
by: Suryakumar Narayanasamy, et al.
Published: (2024-09-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Comparison Of Glucagon Like Peptide/1 Levels In Diabetic Women With Ovarian Polycystic Syndrome And Healthy Women
by: Namra Iqtidar, et al.
Published: (2024-09-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
by: Ortal Resnick, et al.
Published: (2025-01-01)

Evidence for Activation of Toll-Like Receptor and Receptor for Advanced Glycation End Products in Preterm Birth
by: Taketoshi Noguchi, et al.
Published: (2010-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

Role of Matrix Metalloproteinase-8 in Atherosclerosis
by: Sébastien Lenglet, et al.
Published: (2013-01-01)

The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?
by: Fabrizio Montecucco, et al.
Published: (2007-01-01)

The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies
by: Fabrizio Montecucco, et al.
Published: (2009-01-01)

Insulin Resistance: A Proinflammatory State Mediated by Lipid-Induced Signaling Dysfunction and Involved in Atherosclerotic Plaque Instability
by: Fabrizio Montecucco, et al.
Published: (2008-01-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

A New Way for Beta Cell Neogenesis: Transdifferentiation from Alpha Cells Induced by Glucagon-Like Peptide 1
by: Zhen Zhang, et al.
Published: (2019-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Vascular Effects of Dietary Advanced Glycation End Products
by: Alin Stirban, et al.
Published: (2015-01-01)

The effect of protein oxidation on the formation of advanced glycation end products after chicken myofibrillar protein glycation
by: Zongshuai Zhu, et al.
Published: (2023-09-01)

Role of Advanced Glycation End Products in Mediating Glycated Haemoglobin and Pulse Wave Velocity in Healthy Adults
by: Irene Martínez-García, et al.
Published: (2025-01-01)

Do Lactation-Induced Changes in Ghrelin, Glucagon-Like Peptide-1, and Peptide YY Influence Appetite and Body Weight Regulation during the First Postpartum Year?
by: D. Enette Larson-Meyer, et al.
Published: (2016-01-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life
by: P. B. Jeppesen, et al.
Published: (2009-01-01)

A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients
by: David L Sigalet, et al.
Published: (2013-01-01)

Receptor for Advanced Glycation End Products and Its Involvement in Inflammatory Diseases
by: Yaw Kuang Chuah, et al.
Published: (2013-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
by: Feng Sun, et al.
Published: (2015-01-01)

A TRPM4 Inhibitor 9-Phenanthrol Inhibits Glucose- and Glucagon-Like Peptide 1-Induced Insulin Secretion from Rat Islets of Langerhans
by: Zuheng Ma, et al.
Published: (2017-01-01)

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells
by: Jason M. Conley, et al.
Published: (2024-12-01)

The possible therapeutic role of advanced glycation end-product inhibitors in ischemic stroke
by: Nada H. Aljarba, et al.
Published: (2025-03-01)